Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

BACKGROUND: Interleukin 6 (IL-6) signaling plays a key role in the pathophysiology of rheumatoid arthritis (RA) and is inhibited by sarilumab, a human monoclonal antibody blocking the IL-6 receptor alpha (IL-6Rα). The effects of sarilumab plus methotrexate (MTX) on serum biomarkers of joint damage a...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyapati, Anita, Msihid, Jérôme, Fiore, Stefano, van Adelsberg, Janet, Graham, Neil M. H., Hamilton, Jennifer D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052933/
https://www.ncbi.nlm.nih.gov/pubmed/27716324
http://dx.doi.org/10.1186/s13075-016-1132-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052933/
https://www.ncbi.nlm.nih.gov/pubmed/27716324
http://dx.doi.org/10.1186/s13075-016-1132-9

Ejemplares similares